Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia

News
1
1 Like
2

"KarXT

Our lead product candidate, KarXT, selectively activates muscarinic acetylcholine receptors in the brain to unlock the therapeutic potential of xanomeline, which previously demonstrated significant benefits in Phase 2 studies in schizophrenia and Alzheimer’s."

https://karunatx.com/programs/

1 Like